Yahoo
    NasdaqCM - Nasdaq Real Time Price USD

    Jade Biosciences, Inc. (JBIO)

    14.06 -0.18 (-1.26%)
    At close: October 30 at 4:00:01 PM EDT
    14.06 0.00 (0.00%)
    After hours: October 30 at 4:00:16 PM EDT
    Trade JBIO on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for JBIO
    • Previous Close 14.24
    • Open 14.13
    • Bid 10.08 x 200
    • Ask 14.09 x 100
    • Day's Range 13.83 - 14.35
    • 52 Week Range 8.36 - 28.00
    • Volume 682,307
    • Avg. Volume 898,846
    • Market Cap (intraday) 894.179M
    • Beta (5Y Monthly) --
    • PE Ratio (TTM) --
    • EPS (TTM) -1.92
    • Earnings Date (est.) Nov 12, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 50.12
    • Zacks Rating Neutral

    Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

    jadebiosciences.com

    55

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Jade Biosciences, Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    JBIO
    8.88%
    S&P 500 (^GSPC)
    10.73%

    1-Year Return

    JBIO
    42.74%
    S&P 500 (^GSPC)
    11.11%

    3-Year Return

    JBIO
    95.87%
    S&P 500 (^GSPC)
    81.91%

    5-Year Return

    JBIO
    97.41%
    S&P 500 (^GSPC)
    64.59%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue --
    Earnings -55.77M
    Profit Margin 0.00%

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    -50M
    -40M
    -30M
    -20M
    -10M
    0
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    40.00
    50.12 Average
    14.06 Current
    77.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 10/27/2026
    Analyst BTIG
    Rating Action Reiterates
    Rating Buy
    Price Action Maintains
    Price Target 77 -> 77
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      --

    • Return on Equity (ttm)

      --

    • Revenue (ttm)

      --

    • Net Income Avi to Common (ttm)

      -124.44M

    • Diluted EPS (ttm)

      -1.92

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      461.2M

    • Total Debt/Equity (mrq)

      0.32%

    • Levered Free Cash Flow (ttm)

      --

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    GLUE Monte Rosa Therapeutics, Inc.
    10.76 -1.01%
    TYRA Tyra Biosciences, Inc.
    21.07 -1.91%
    DSGN Design Therapeutics, Inc.
    10.68 -3.44%
    ABOS Acumen Pharmaceuticals, Inc.
    0.2101 -90.83%
    EWTX Edgewise Therapeutics, Inc.
    38.90 -0.03%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: